Terug
23
33
Dagbereik
€ 0,93
€ 1,35
52-Weeksbereik
€ 0,93
€ 1,64
Volume
110
50D / 200D Gem.
€ 1,35
/
€ 1,31
Vorige Slotkoers
€ 1,35
Quick Summary
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 2,3 | 0,4 |
| P/B | 0,2 | 2,9 |
| ROE % | 8,6 | 3,9 |
| Net Margin % | 18,1 | 3,8 |
| Rev Growth 5Y % | -1,0 | 10,0 |
| D/E | 0,0 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2028 |
€ 1,23
€ 1,11 – € 1,31
|
14,83B | 1 |
| FY2027 |
€ 1,01
€ 0,91 – € 1,07
|
11,99B | 1 |
| FY2026 |
€ 0,85
€ 0,76 – € 0,90
|
9,98B | 1 |
No quarterly estimates available
Dividend History
Yield
0,03%
Payout Ratio
N/A
Growth (3Y)
N/A
Growth (5Y)
N/A
No dividend history available.
Belangrijkste Punten
Revenue declined -1,03% annually over 5 years
Earnings declined -10,45% over the past year
Net margin of 18,13% shows strong profitability
Debt/Equity of 0,04 — conservative balance sheet
Generating 812,64M in free cash flow
P/E of 2,26 — trading at a low valuation
Groei
Revenue Growth (5Y)
-1,03%
Revenue (1Y)7,11%
Earnings (1Y)-10,45%
FCF Growth (3Y)-48,20%
Kwaliteit
Return on Equity
8,60%
ROIC6,37%
Net Margin18,13%
Op. Margin19,22%
Veiligheid
Debt / Equity
0,04
Current Ratio6,33
Interest Coverage77,77
Waardering
P/E Ratio
2,26
Forward P/EN/A
P/B Ratio0,19
EV/EBITDA0,82
Dividend Yield0,03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 7,11% | Revenue Growth (3Y) | -0,08% |
| Earnings Growth (1Y) | -10,45% | Earnings Growth (3Y) | -22,27% |
| Revenue Growth (5Y) | -1,03% | Earnings Growth (5Y) | -16,73% |
| Profitability | |||
| Revenue (TTM) | 8,00B | Net Income (TTM) | 1,45B |
| ROE | 8,60% | ROA | 7,55% |
| Gross Margin | 71,50% | Operating Margin | 19,22% |
| Net Margin | 18,13% | Free Cash Flow (TTM) | 812,64M |
| ROIC | 6,37% | FCF Growth (3Y) | -48,20% |
| Safety | |||
| Debt / Equity | 0,04 | Current Ratio | 6,33 |
| Interest Coverage | 77,77 | ||
| Dividends | |||
| Dividend Yield | 0,03% | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 2,26 | Forward P/E | N/A |
| P/B Ratio | 0,19 | P/S Ratio | 0,41 |
| PEG Ratio | -1,51 | Forward PEG | N/A |
| EV/EBITDA | 0,82 | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 24,80% | ||
| Market Cap | 3,28B | Enterprise Value | 1,26B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 8,00B | 7,47B | 8,01B | 9,15B | 8,34B |
| Net Income | 1,45B | 1,62B | 2,40B | 3,26B | 3,02B |
| EPS (Diluted) | 0,60 | 0,67 | 0,98 | 1,33 | 1,22 |
| Gross Profit | 5,72B | 5,42B | 6,08B | 7,04B | 6,25B |
| Operating Income | 1,54B | 1,73B | 2,71B | 3,55B | 3,15B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 19,21B | 18,05B | 17,73B | 17,75B | 15,81B |
| Total Liabilities | 1,66B | 1,64B | 2,17B | 3,02B | 2,96B |
| Shareholders' Equity | 17,40B | 16,31B | 15,52B | 14,59B | 12,75B |
| Total Debt | 690,43M | 860,74M | 1,30B | 1,81B | 1,71B |
| Cash & Equivalents | 2,70B | 3,71B | 4,31B | 4,38B | 3,39B |
| Current Assets | 9,30B | 8,70B | 8,79B | 8,83B | 7,38B |
| Current Liabilities | 1,47B | 1,52B | 2,05B | 2,88B | 2,08B |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#702 of 827
#286 of 709
Recente Activiteit
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026